Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Views & Analysis Value for money of Health Technology Assessment Health Technology Assessment (HTA), despite the many definitions in use, has become almost synonymous with value for money (VfM). But just what is the value for money of HTA itself?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.